News | Women's Health | July 21, 2015

Scientific study confirms reduced variation between exam results with automated density measurements

July 21, 2015 - Researchers at the University of Virginia (UVA) Health System have demonstrated that automated volumetric fibroglandular breast density measurement tools are more precise than area-based methods.  Results of the study, "Reliability of Automated Breast Density Measurements," recently featured in Radiology, suggest that with lower variability, volumetric breast density is well suited for inclusion in breast cancer risk models. The announcement was made at The Association for Medical Imaging Management (AHRA)'s 43rd annual meeting and exposition, July 19-22 in Las Vegas. 

"Breast density is increasingly being considered with other known risk factors to improve risk prediction in order to give women personalized knowledge to make decisions about screening. However, variability in assigned density category may result in changes in recommendations for adjuvant screening. Thus, for consistency, objectivity, and ease of use, breast density measurement ideally should be automated and accurate," said Jennifer Harvey, M.D., professor of radiology at the UVA School of Medicine. "The purpose of this study was to estimate the reliability of area-based methods and automated volumetric breast density measurements using repeated measures."

Thirty women undergoing screening mammography consented to undergo a repeated left craniocaudal examination performed by a second technologist in this prospective study. Breast density was measured by using both area-based and volumetric methods (Volpara software). Discrepancy between the first and second breast density measurements was obtained for each algorithm by subtracting the second measurement from the first and then analyzed with a random-effects model to derive limits of measurement agreement. 

Results of the study demonstrate that variability in a repeated measurement of breast density is highest for area-based measurement tools, standard deviation 3.32 percent (2.65-4.44). In contrast, precision was highest for automated volumetric breast density tools, such as VolparaDensity, standard deviation 0.99 percent (0.79-1.33).  

"The excellent reproducibility of automated breast density measurements indicates that they would be well suited for inclusion in a breast cancer risk model.  This is consistent with results we presented at the San Antonio Breast Cancer Symposium in December that showed that the addition of volumetric breast density improved breast cancer risk discrimination," Harvey added.

For more information: www.uvahealth.com


Related Content

News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Women's Health

April 16, 2026 – GE HealthCare has expanded its collaboration with DeepHealth, Inc., a wholly-owned subsidiary of RadNet ...

Time April 20, 2026
arrow
News | Breast Imaging

April 15, 2026 — QT Imaging Holdings, Inc. has launched its QTI Imaging-Olea Viewer, developed in collaboration with ...

Time April 15, 2026
arrow
News | Breast Imaging

April 1, 2026 — QT Imaging Holdings has released its latest image reconstruction software update, version 4.5.0. This ...

Time April 02, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Breast Imaging

March 30, 2026 — Each year, the Alumni Association at the University of Missouri-Kansas City, recognizes the ...

Time March 31, 2026
arrow
News | MRI Breast | Breast cancer, dense breast, MRI

March 2, 2026 — A collaborative modeling study found that adding biennial breast magnetic resonance imaging (MRI) to ...

Time March 20, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
Subscribe Now